UPCC 06523 Characterization Of Factors Associated With Response And Survival In Lung Cancer Patients Treated With Immuno-Oncology Agents (IO’s): A Protocol For The Collection Of Archival Tissue And Maintenance Of An Immuno-Oncology Database

Enrolling By Invitation
99 years or below
All
Phase N/A
10000 participants needed
1 Location

Brief description of study

This study's primary objective will be to create a database of lung cancer patients treated with immunotherapy agents and to access Remnant (left-over) tissue collected from clinically-indicated procedures/surgery for analyses, to determine factors that predict response to immunotherapy, and/or the toxicity prole of patients treated with immunotherapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 18-0874
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator